STAT2 min read
STAT+: Pharmalittle: We’re Reading About AstraZeneca CEO Pay, Alternatives To WuXi And More
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.…
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Drug Shortages, Medicare Spending On An Alzheimer’s Drug, And More
Medicare estimates a new Alzheimer’s drug could cost the program billions of dollars by next year — well beyond what Wall Street or the drug’s manufacturer project.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A 486% Drug Price Hike, AstraZeneca CEO Pay, And More
Is there any circumstance when a 486% increase for a medicine might be justified? A small company called Harrow argues the case for an injectable eye treatment.
STAT1 min readAmerican Government
Opinion: As A Rule, Rape Exceptions For Abortion Don’t Work
Abortion opponents often say they want to support survivors of rape. But abortion bans do the opposite, and no fake "rape exception" is going to change that.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biotech Startups, Pfizer’s RSV Vaccine, And More
Biotech startups recently closed out their best fundraising quarter in two years, signaling that the industry downturn may soon be a thing of the past.
STAT1 min read
STAT+: HCA Reports Almost $1 Billion More In Charity Care To Medicare Than To Its Shareholders, Drawing More Taxpayer Money
HCA Healthcare, the country's biggest hospital chain, reported almost $1 billion more in charity care to CMS than in its financial statement, drawing more taxpayer money.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Biocon Eyeing Weight Loss Drugs, Sanofi Layoffs, And More
Biocon is pivoting to weight loss drugs as patents for the blockbuster medicines start to expire, unleashing a coming wave of generics.
STAT1 min read
STAT+: Nuclear Regulatory Commission Advisers Beset By Conflicts Of Interest, Report Finds
Advisers to the Nuclear Regulatory Commission, a U.S. government agency tasked with ensuring the safe use of radioactive materials, were beset by conflicts of interest, report finds
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Boehringer Biosimilar Frustrations, FTC Warnings, And More
Boehringer Ingelheim will lay off an undisclosed number of sales reps due to poor U.S. sales of its biosimilar version of AbbVie’s blockbuster arthritis treatment Humira.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Amylyx Pulling Its ALS Drug, GLP-1 Drugs For Parkinson’s, And More
Amylyx Pharmaceuticals will take its ALS drug Relyvrio off the market in the U.S. and Canada, ending a multi-year saga for patients with the rare neurodegenerative disease.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A White House Drug-shortage Plan, A Genmab Deal, And More
A White House plan to stem drug shortages involves basing Medicare payments on whether hospitals adopt business practices that avoid shortages.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A European Probe Into Vaccine Talks; Net Drug Prices Falling, And More
Top European prosecutors are investigating allegations of criminal wrongdoing in connection with the European Commission president's vaccine negotiations with Pfizer.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About AstraZeneca’s CEO Pay, An ALS Drug Spat In The U.K., And More
AstraZeneca’s plan to pay CEO Pascal Soriot up to £18.7 million has been branded “excessive” by two shareholder advisers.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Wegovy Insurance Coverage, Zepbound Shortages, And More
The first major U.S. health insurers have agreed to start paying for the Wegovy weight loss drug for certain people on Medicare with heart conditions.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A GLP-1 Side Effect, U.K. Clinical Trial Transparency, And More
A new study links GLP-1 drugs like Ozempic to a higher risk of aspiration pneumonia — a lung infection caused by food breathed into the lungs — after endoscopies.
STAT1 min read
STAT+: AstraZeneca Sues Arkansas Over The Role Of Pharmacies In A Federal Discount Drug Program
AstraZeneca filed a lawsuit seeking to block an Arkansas law that requires the company to ship its medicines to any pharmacy working with hospitals participating in a federal discount program.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Abortion Pill Arguments, A Merck Drug Approval, And More
U.S. Supreme Court justices focused on plaintiffs' right to sue the FDA to reinstate restrictions on a commonly used abortion pill, suggesting they are unlikely to restrict access.
STAT1 min read
STAT+: Borrowing An Idea From Cancer Immunotherapy, Scientists Make Old-mice Immune Systems Youthful Again
The Stanford lab of Irv Weissman channeled its cancer-targeting expertise to tip the immune systems of aged mice back to a youthful state.
STAT4 min read
STAT+: Pharmalittle: We’re Reading About Amgen Suing Colorado Over Drug Price Caps, Abortion Pills, And More
Amgen accused a Colorado board of violating the U.S. Constitution with its first-in-the-nation plan to cap the cost of a pricey prescription medicine.
STAT1 min read
Disparities In Donor Acceptance Rates Point To Need For More Equitable Heart Transplant Care
While access to donor hearts has increased, there are still gender- and race-based disparities in the acceptance rate of a donor heart offer by transplant teams, a new study finds.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About A Novo Nordisk Deal, A Regeneron Setback, And More
Novo Nordisk agreed to acquire Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional cardiometabolic drug candidates.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Medicare And Obesity Drugs, FDA Syringe Warnings, And More
This morning in the Pharmalittle roundup: We're reading about Medicare and obesity drugs, FDA syringe warnings, and more.
STAT2 min read
Opinion: STAT+: Medical Devices Makers Are Trying To Take A Page From Uber’s Playbook
When it comes to device makers, regulators and payers should be on the lookout for Uber-like behavior — including aggressive marketing strategies.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Medicare And Obesity Drugs, GSK Asthma Inhalers, And More
The Congressional Budget Office forecast that Medicare will likely choose the obesity drug semaglutide for price negotiation “within the next few years.”
STAT1 min read
STAT+: U.K. Health Officials And Researchers Try To Carve A Path For More Individualized Genetic Treatments
Researchers and government agencies in the U.K. are trying to figure out how to best advance individualized genetic treatments.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About Europe’s Pharma Reform, Weight-loss Meds, And More
Weight-loss medications are not reaching the people who need them most, and white adults were more likely than Asian or Black adults to get them in a new study.
STAT1 min read
STAT+: New Gene Therapy, To Be Priced At $4.25 Million, Has Already Transformed Children’s Lives
The world's most expensive treatment offers a near-cure for young children and redemption for its developer, but steep challenges still loom.
STAT1 min read
STAT+: Medicare Expected To Negotiate Obesity Drug Prices Soon, New Analysis Predicts
Medicare will likely choose the obesity drug semaglutide for price negotiation “within the next few years,” according to a new analysis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An AstraZeneca Deal, A WHO Pandemic Pact, And More
AstraZeneca agreed to acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on targeted radiation therapies for cancer.
STAT2 min readAddiction
STAT+: The Methadone Clinic Monopoly: Opioid Treatment Chains Backed By Private Equity Are Fighting Calls For Reform
Private equity’s surging interest in the methadone treatment industry adds a new layer to the fraught and fast-shifting debate over access to addiction medications.
…Or Discover Something New